Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportOncology: Basic, Translational & Therapy

Progress in first-in-human trial of Hsp90-targeted PET imaging in cancer patients

Mark Dunphy, Gabriela Chiosis, Bradley Beattie, Gerecitano John, Jackie Bromberg, Yelena Janjigian, Susan Slovin, Pat Zanzonico, Jason Lewis and Steven Larson
Journal of Nuclear Medicine May 2013, 54 (supplement 2) 279;
Mark Dunphy
1Memorial Sloan-Kettering Cancer Center, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gabriela Chiosis
1Memorial Sloan-Kettering Cancer Center, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bradley Beattie
1Memorial Sloan-Kettering Cancer Center, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gerecitano John
1Memorial Sloan-Kettering Cancer Center, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jackie Bromberg
1Memorial Sloan-Kettering Cancer Center, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yelena Janjigian
1Memorial Sloan-Kettering Cancer Center, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susan Slovin
1Memorial Sloan-Kettering Cancer Center, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pat Zanzonico
1Memorial Sloan-Kettering Cancer Center, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jason Lewis
1Memorial Sloan-Kettering Cancer Center, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven Larson
1Memorial Sloan-Kettering Cancer Center, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

279

Objectives Provide an update on PET microdose clinical trial of I-124 PUH71, a radiolabeled heat shock protein 90 (Hsp90) inhibitor, in an expanded cohort of cancer types.

Methods Trial performed under IRB-approved protocol and US FDA-approved IND. Main eligibility criteria: >18 years; evaluable tumors on clinical imaging; serum liver and renal indices within specified range; no hyperthyroidism. I-124 PUH71 tracer microdose injected peripheral IV. PET-CT scans obtained at multiple time-points up to 7-8 days, post-injection. Serial blood sampling for activity and metabolite assays. MIRD formalism and OLINDA software used for dosimetry analyses of PET-derived and blood time-activity data.

Results 20 patients to-date, with breast (n=9), lymphoma (NHL n=4; Hodgkin=1), pancreatic (n=2), neuroblastoma (n=2), fallopian tube (n=1), and prostate (n=1) cancers. PUH71 tracer safe in all 20 patients. Learned optimal PET protocol for tumor imaging. Variety of histological types of tumors evident on PUH71 PET (Suppl Fig. 1). PUH71 biodistribution suggests other potential PET clinical applications.

Conclusions Our expanded trial data demonstrates the feasibility of detecting tumors in human subjects by Hsp90-targeted PET in a wider variety of human cancers than we previously reported. Further development of I-124 PUH71 as a first-of-its-kind Hsp90-targeted PET imaging agent ongoing, including new clinical applications.

Research Support Clinical trial supported by Samus Therapeutics; MSKCC Breast Cancer Research Fund 3 Preclinical development supported by ICMIC P50 CA 086438; SAIRP grant R24 CA83084; and the Cyclotron-Radiochemistry Core of MSKCC.

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 54, Issue supplement 2
May 2013
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Progress in first-in-human trial of Hsp90-targeted PET imaging in cancer patients
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Progress in first-in-human trial of Hsp90-targeted PET imaging in cancer patients
Mark Dunphy, Gabriela Chiosis, Bradley Beattie, Gerecitano John, Jackie Bromberg, Yelena Janjigian, Susan Slovin, Pat Zanzonico, Jason Lewis, Steven Larson
Journal of Nuclear Medicine May 2013, 54 (supplement 2) 279;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Progress in first-in-human trial of Hsp90-targeted PET imaging in cancer patients
Mark Dunphy, Gabriela Chiosis, Bradley Beattie, Gerecitano John, Jackie Bromberg, Yelena Janjigian, Susan Slovin, Pat Zanzonico, Jason Lewis, Steven Larson
Journal of Nuclear Medicine May 2013, 54 (supplement 2) 279;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oncology: Basic, Translational & Therapy

  • The frequency and content of documentation for patients’ 131I therapies for checkpoint security agents: the final report of a national survey.
  • Physician and Nurse Radiation Exposure During the First Year of Performing I-131 mIBG Therapy
  • Impact of Inter-software and Inter-reader Agreement on FDG PET/CT Liver SULmean
Show more Oncology: Basic, Translational & Therapy

Basic Science (Oncology): Clinical Pilot Studies

  • PSMA targeted SPECT imaging biomarker to detect local and metastatic prostate cancer (PCa): Phase I studies with 99mTc-MIP-1404
  • Ex vivo SPECT/CT imaging of prostate cancer via 111In-J591 monoclonal antibody
  • Relative biodistribution and tumor uptake of 124I-CLR1404 (aka NM404) in non-small cell lung cancer (NSCLC) patients
Show more Basic Science (Oncology): Clinical Pilot Studies

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire